CLRPF
Price
$2.38
Change
+$0.32 (+15.53%)
Updated
Jul 16 closing price
Capitalization
733.6M
DOSEF
Price
$0.96
Change
+$0.04 (+4.35%)
Updated
Jul 15 closing price
Capitalization
4.92M
Interact to see
Advertisement

CLRPF vs DOSEF

Header iconCLRPF vs DOSEF Comparison
Open Charts CLRPF vs DOSEFBanner chart's image
Clarity Pharmaceuticals
Price$2.38
Change+$0.32 (+15.53%)
Volume$5.68K
Capitalization733.6M
Doseology Sciences
Price$0.96
Change+$0.04 (+4.35%)
Volume$100
Capitalization4.92M
CLRPF vs DOSEF Comparison Chart in %
Loading...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DOSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLRPF vs. DOSEF commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLRPF is a Buy and DOSEF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (CLRPF: $2.38 vs. DOSEF: $1.00)
Brand notoriety: CLRPF and DOSEF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLRPF: 87% vs. DOSEF: 11%
Market capitalization -- CLRPF: $733.6M vs. DOSEF: $4.92M
CLRPF [@Biotechnology] is valued at $733.6M. DOSEF’s [@Biotechnology] market capitalization is $4.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLRPF’s FA Score shows that 0 FA rating(s) are green whileDOSEF’s FA Score has 0 green FA rating(s).

  • CLRPF’s FA Score: 0 green, 5 red.
  • DOSEF’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLRPF and DOSEF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLRPF’s TA Score shows that 6 TA indicator(s) are bullish while DOSEF’s TA Score has 3 bullish TA indicator(s).

  • CLRPF’s TA Score: 6 bullish, 3 bearish.
  • DOSEF’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, CLRPF is a better buy in the short-term than DOSEF.

Price Growth

CLRPF (@Biotechnology) experienced а +21.43% price change this week, while DOSEF (@Biotechnology) price change was +9.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.62%, and the average quarterly price growth was +40.41%.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLRPF($734M) has a higher market cap than DOSEF($4.92M). DOSEF YTD gains are higher at: 611.744 vs. CLRPF (-12.015). DOSEF has higher annual earnings (EBITDA): -296.52K vs. CLRPF (-66.98M).
CLRPFDOSEFCLRPF / DOSEF
Capitalization734M4.92M14,916%
EBITDA-66.98M-296.52K22,590%
Gain YTD-12.015611.744-2%
P/E RatioN/AN/A-
RevenueN/A46.7K-
Total CashN/A820K-
Total DebtN/A0-
TECHNICAL ANALYSIS
Technical Analysis
CLRPFDOSEF
RSI
ODDS (%)
Bearish Trend 1 day ago
65%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
61%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
51%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
54%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
75%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DOSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYUIX62.67N/A
N/A
Rydex Utilities Inv
AEMMX12.29N/A
N/A
American Century Emerging Markets A
MTRIX19.66N/A
N/A
MFS Total Return I
IIVLX20.34N/A
N/A
Transamerica Small/Mid Cap Value C
WEIMX17.22N/A
N/A
TETON Westwood Mighty Mites I

CLRPF and

Correlation & Price change

A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRPF
1D Price
Change %
CLRPF100%
N/A
SBHMY - CLRPF
24%
Poorly correlated
N/A
BOLD - CLRPF
23%
Poorly correlated
+3.51%
AKBA - CLRPF
21%
Poorly correlated
-0.51%
DOSEF - CLRPF
12%
Poorly correlated
+4.17%
ACUT - CLRPF
9%
Poorly correlated
-2.22%
More

DOSEF and

Correlation & Price change

A.I.dvisor tells us that DOSEF and MNPR have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DOSEF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DOSEF
1D Price
Change %
DOSEF100%
+4.17%
MNPR - DOSEF
24%
Poorly correlated
+15.05%
AKRO - DOSEF
23%
Poorly correlated
+1.36%
SGMT - DOSEF
21%
Poorly correlated
-0.10%
ADAG - DOSEF
21%
Poorly correlated
-14.21%
CLRPF - DOSEF
12%
Poorly correlated
N/A
More